Ludger Klimek1, Oliver Pfaar. 1. Allergy Center, An den Quellen 10, D-65183 Wiesbaden, Germany. ludger.klimek@allergiezentrum.org
Abstract
BACKGROUND: Allergic diseases are among the most common diseases in humans. Besides allergen avoidance, allergen-specific immunotherapy is the only causative treatment option. During recent years, many innovations of this therapy have emerged. METHODS: Selective literature research in Medline and PubMed, under the inclusion of national and international guidelines and Cochrane meta analyses. RESULTS: In several meta-analyses, the clinical efficacy of subcutaneous immunotherapy (SCIT) has been largely demonstrated. Recently, major research activities in mucosal immunotherapies focused on the sublingual application route. There are well-documented clinical data on the efficacy and safety of this form of immunotherapy. New application routes as well as new immune-modifying agents such as virus-like particles or CpG-motifs have also been investigated. CONCLUSION: SIT is accepted to be the only causative treatment option for allergies. New application routes and new immune-modifying agents will allow for different delivery methods in the future.
BACKGROUND:Allergic diseases are among the most common diseases in humans. Besides allergen avoidance, allergen-specific immunotherapy is the only causative treatment option. During recent years, many innovations of this therapy have emerged. METHODS: Selective literature research in Medline and PubMed, under the inclusion of national and international guidelines and Cochrane meta analyses. RESULTS: In several meta-analyses, the clinical efficacy of subcutaneous immunotherapy (SCIT) has been largely demonstrated. Recently, major research activities in mucosal immunotherapies focused on the sublingual application route. There are well-documented clinical data on the efficacy and safety of this form of immunotherapy. New application routes as well as new immune-modifying agents such as virus-like particles or CpG-motifs have also been investigated. CONCLUSION:SIT is accepted to be the only causative treatment option for allergies. New application routes and new immune-modifying agents will allow for different delivery methods in the future.
Authors: Andrzej Bozek; Aleksandra Foks; Karolina Trzaska; Giorgio Walter Canonica Journal: Postepy Dermatol Alergol Date: 2019-05-27 Impact factor: 1.837